New York Post was hot off the press on October 26, 2020, with positive news from AstraZeneca’s trials. The British multinational pharmaceutical and bio pharmaceutical company announced further positive responses to its COVID-19 vaccine currently trialing. Moreover, the broad immune response to their Oxford Vaccine is similar among both older and younger adults. Could the data be hinting at a more universal vaccine for the disease?
Older Folk Safer in the Broad Immune Response to Oxford Vaccine
The adverse reactions are also lower among older folk. AstraZeneca told Reuters it was delighted by similar immune responses, with fewer older negative ones. The latter is especially significant, because COVID-19 severity increases as metabolism ages.
‘These results add further proof of Oxford Vaccine’s ability to provoke the desired response safely,’ the company spokesperson said. This is important because the human immune system weakens with age, and puts older people at more risk of dying. The Financial Times similarly reports ‘robust immune responses’ among the 18 to 55 age group.
British Health Secretary Preparing for Possible Roll Out
This broad immune response to Oxford Vaccine does not yet mean we have a runner vaccine yet. However, British Health Secretary Matt Hancock is ‘preparing logistics for a possible rollout’ according to New York Post.
He expects the rollout to materialize in numbers in the first half of 2021, although he would not rule out some people having their shots sooner. ‘We want to be ready in case everything goes perfectly,’ he explains. ‘But it’s not my central expectation that we’ll be doing that this year. We’re not there yet, although the program is progressing well’.
Breaking news is a London hospital is on standby to start vaccinating thousands of doctors, nurses and other front line workers. That’s just as soon as they receive their first batch of the Oxford Vaccine we are all holding thumbs for.
Related
Oxford COVID-19 Trials Enter Stage 3
Oxford Vaccine Makes Antibodies and T-Cells
Preview Image: AstraZeneca R&D Facility
